Fraxetin

Fraxetin’s distinctive hook. Its 7,8-catechol makes it a strong radical scavenger with in-vivo/ex-vivo antioxidant and lipid-peroxidation-lowering activity ^{2,3Reference 2Fernandez-Puntero B et al. · 2001Antioxidant activity of fraxetin: in-vivo and ex-vivo parameters in normal versus induced stressView study →Reference 3Martín-Aragón S et al. · 1997AnimalModifications of antioxidant capacity and lipid peroxidation in mice under fraxetin treatmentView study →}, and an iron chelator/reductant whose direction is context-dependent: in plant roots it reduces and mobilizes Fe(III) (a siderophore-like, pro-redox role) ^{4Reference 4Tsai HH et al. · 2018Scopoletin 8-hydroxylase-mediated fraxetin production is crucial for iron mobilisationView study →}, while in disease models it restrains iron-dependent ferroptotic lipid peroxidation via Nrf2/HO-1/GPX4 ^{5Reference 5Xu Y et al. · 2021Fraxetin attenuates ferroptosis in myocardial infarction via AKT/Nrf2/HO-1 signallingView study →} and by blocking NCOA4-mediated ferritinophagy ^{6Reference 6Zhai X et al. · 2023Fraxetin alleviates bleomycin-induced pulmonary fibrosis by inhibiting NCOA4-mediated epithelial-cell ferroptosisView study →}.

Gap: the two iron literatures barely reference each other, there is no human antioxidant readout, and “iron chelator” is a chemical property, not a demonstrated therapeutic in people ^{4,5Reference 4Tsai HH et al. · 2018Scopoletin 8-hydroxylase-mediated fraxetin production is crucial for iron mobilisationView study →Reference 5Xu Y et al. · 2021Fraxetin attenuates ferroptosis in myocardial infarction via AKT/Nrf2/HO-1 signallingView study →}.

A reproducible NF-κB-restraint signal shared with the sibling coumarins: fraxetin inhibits IKKβ to block NF-κB and the NLRP3 inflammasome in septic spleen injury ^{7Reference 7Huangfu L et al. · 2025Fraxetin inhibits IKKβ, blocks NF-κB and NLRP3 inflammasome activation, and alleviates spleen injury in sepsisView study →}, acts anti-inflammatory/antifibrotic in chronic pancreatitis ^{8Reference 8Balaha M et al. · 2021AnimalFraxetin prevented sodium-fluoride-induced chronic pancreatitis in ratsView study →}, and protects IL-1β-driven chondrocytes ^{9Reference 9Wang Q et al. · 2020Fraxetin inhibits IL-1β-induced apoptosis, inflammation and matrix degradation in chondrocytesView study →}.

Gap: all acute rodent/cell models, in single-lab clusters, with no human data ^{7,8Reference 7Huangfu L et al. · 2025Fraxetin inhibits IKKβ, blocks NF-κB and NLRP3 inflammasome activation, and alleviates spleen injury in sepsisView study →Reference 8Balaha M et al. · 2021AnimalFraxetin prevented sodium-fluoride-induced chronic pancreatitis in ratsView study →}.

The most internally consistent organ-protection theme: fraxetin reduces CCl₄-induced liver fibrosis via NF-κB/IκBα, MAPK and Bcl-2/Bax ^{10Reference 10Wu B et al. · 2019Antifibrotic effects of fraxetin on CCl₄-induced liver fibrosis via NF-κB/IκBα, MAPKs and Bcl-2/BaxView study →} and mitigates ethanol-induced hepatic fibrosis by enhancing ethanol metabolism and lowering oxidative stress ^{11Reference 11Chen X et al. · 2018Therapeutic effect of fraxetin on ethanol-induced hepatic fibrosisView study →}.

Gap: the classic “reduce oxidative stress in a toxin model” design, rodent only ^{10,11Reference 10Wu B et al. · 2019Antifibrotic effects of fraxetin on CCl₄-induced liver fibrosis via NF-κB/IκBα, MAPKs and Bcl-2/BaxView study →Reference 11Chen X et al. · 2018Therapeutic effect of fraxetin on ethanol-induced hepatic fibrosisView study →}.

Fraxetin reduced microglia-mediated neuroinflammation after ischemic stroke ^{12Reference 12Deng SJ et al. · 2022Fraxetin alleviates microglia-mediated neuroinflammation after ischemic strokeView study →} and produced antidepressant-like effects in a chronic-unpredictable-stress model ^{13Reference 13Ahmed Z et al. · 2023Fraxetin attenuates disrupted behavioural and central neurochemical activity in chronic unpredictable stressView study →}.

Gap: heterogeneous acute models with no convergent mechanism and no clinical work ^{12,13Reference 12Deng SJ et al. · 2022Fraxetin alleviates microglia-mediated neuroinflammation after ischemic strokeView study →Reference 13Ahmed Z et al. · 2023Fraxetin attenuates disrupted behavioural and central neurochemical activity in chronic unpredictable stressView study →}.

Fraxetin induces apoptosis/mitochondrial dysfunction in hepatocellular-carcinoma cells ^{14Reference 14Song J et al. · 2021Fraxetin suppresses cell proliferation and induces apoptosis via mitochondrial dysfunction in hepatocellular-carcinoma cellsView study →} and, as the traditionally “anti-dysenteric” coumarin, sensitizes pancreatic cancer to gemcitabine ^{15Reference 15Guo Y et al. · 2021The anti-dysenteric drug fraxetin enhances gemcitabine efficacy and suppresses pancreatic-cancer developmentView study →}.

Gap: a broad but shallow cell-line literature — almost entirely in-vitro, across scattered targets, with no in-vivo efficacy standard ^{14,15Reference 14Song J et al. · 2021Fraxetin suppresses cell proliferation and induces apoptosis via mitochondrial dysfunction in hepatocellular-carcinoma cellsView study →Reference 15Guo Y et al. · 2021The anti-dysenteric drug fraxetin enhances gemcitabine efficacy and suppresses pancreatic-cancer developmentView study →}.